Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese
Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese
复制标题
DOI：
10.1016/j.soard.2007.10.011
复制
发表时间：
2008-05-01
影响因子：
3.1
通讯作者：
Brancatisano, Roy
中科院分区：
文献类型：
--
作者：
Brancatisano, Anthony;Wahlroos, Sara;Brancatisano, Roy
背景：评价瑞典可调节胃束带在治疗2型糖尿病(T2 DM)、糖耐量减低(IGT)和病态肥胖症(MS)患者中的疗效。方法：我们从2001年1月至2007年4月连续905名接受瑞典可调节胃带置入术的患者的数据库中确定了所有T2 DM、IGT或MS患者。我们的多学科团队对患者进行了随访，他们的T2 DM由他们的初级保健医生和/或内分泌科医生进行管理。结果：总共有682名患者获得了6个月的随访。在这些患者中，78例有T2 DM，有IGT，100例有MS，中位随访12.5个月，T2 DM患者平均+/-SD超重减轻38%+/-15%。这与血红蛋白A1c和空腹血糖水平从8.0%+/-1.7%降至6.1%+/-1.0%有关(P
Background: To assess the efficacy of the Swedish adjustable gastric band in the treatment of type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT), and the metabolic syndrome (MS) in the morbidly obese.Methods: We identified all patients with T2DM, IGT, or the MS at surgery from our database of 905 consecutive patients who had undergone placement of the Swedish adjustable gastric band between January 2001 and April 2007. The patients were followed up by our multidisciplinary team, and their T2DM was managed by their treating primary care physician and/or endocrinologist.Results: A total of 682 patients had >6 months of follow-up. Of these, 78 patients had T2DM, 64 had IGT, and 100 had the MS. At a median follow-up of 12.5 months, patients with T2DM had a mean +/- SD excess weight loss of 38% +/- 15%. This was associated with hemoglobin A1c and fasting blood sugar levels decreasing from 8.0% +/- 1.7% to 6.1% +/- 1.0% (P